| P50 | author | Rolf Fendel | Q38801275 |
| | Stefan Barth | Q38801300 |
| | Elena Grieger | Q96001312 |
| P2093 | author name string | Rainer Fischer | |
| | Christoph Stein | |
| | Judith Niesen | |
| | Gerrit Gresch | |
| | Mira Woitok | |
| P2860 | cites work | High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells | Q24548319 |
| | Advances in anticancer immunotoxin therapy | Q28085551 |
| | Antibody therapy of cancer | Q28262538 |
| | Tumor regression in cancer patients by very low doses of a T cell-engaging antibody | Q28290910 |
| | CD13 is a therapeutic target in human liver cancer stem cells | Q30496324 |
| | A recombinant bispecific single-chain Fv antibody against HLA class II and FcgammaRIII (CD16) triggers effective lysis of lymphoma cells | Q33200753 |
| | Target-specific cytotoxic activity of recombinant immunotoxin scFv(MUC1)-ETA on breast carcinoma cells and primary breast tumors | Q33274415 |
| | Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells | Q33523138 |
| | Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis | Q33890198 |
| | Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: chemistry, biological evaluations, and therapeutic prospects. | Q33990607 |
| | Immunotoxin treatment of cancer | Q34000417 |
| | Aminopeptidase N (CD13) as a target for cancer chemotherapy | Q34157418 |
| | Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies | Q34548319 |
| | Methylation-associated partial down-regulation of mesothelin causes resistance to anti-mesothelin immunotoxins in a pancreatic cancer cell line | Q35214050 |
| | NK cells: innate immunity against hematological malignancies? | Q35774154 |
| | Single chain antibody fragments with pH dependent binding to FcRn enabled prolonged circulation of therapeutic peptide in vivo | Q35961810 |
| | Efficacy of an adapted granzyme B-based anti-CD30 cytolytic fusion protein against PI-9-positive classical Hodgkin lymphoma cells in a murine model | Q36736543 |
| | Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system | Q36846512 |
| | Immunotoxins: the role of the toxin | Q37139525 |
| | Microtubule-associated protein tau facilitates the targeted killing of proliferating cancer cells in vitro and in a xenograft mouse tumour model in vivo | Q37182201 |
| | The moonlighting enzyme CD13: old and new functions to target | Q37208033 |
| | CD13-positive bone marrow-derived myeloid cells promote angiogenesis, tumor growth, and metastasis | Q37409487 |
| | A dual-targeting triplebody mediates preferential redirected lysis of antigen double-positive over single-positive leukemic cells | Q37593702 |
| | Prospects of bacterial and plant protein-based immunotoxins for treatment of cancer | Q38196312 |
| | A novel fully-human cytolytic fusion protein based on granzyme B shows in vitro cytotoxicity and ex vivo binding to solid tumors overexpressing the epidermal growth factor receptor | Q38791314 |
| | An EGFR/CD13 bispecific fusion protein and its enediyne-energized analog show potent antitumor activity | Q39085089 |
| | Multimerization of anti-(epidermal growth factor receptor) IgG fragments induces an antitumor effect: the case for humanized 528 scFv multimers | Q39119871 |
| | A recombinant triplebody with specificity for CD19 and HLA-DR mediates preferential binding to antigen double-positive cells by dual-targeting. | Q39397717 |
| | Compatible-solute-supported periplasmic expression of functional recombinant proteins under stress conditions | Q39485825 |
| | Aminopeptidase-N/CD13 is a potential proapoptotic target in human myeloid tumor cells | Q39544012 |
| | A single chain immunotoxin, targeting the melanoma-associated chondroitin sulfate proteoglycan, is a potent inducer of apoptosis in cultured human melanoma cells | Q40002915 |
| | Aminopeptidase N (APN/CD13) as a target molecule for scirrhous gastric cancer | Q40100647 |
| | Novel angiogenin mutants with increased cytotoxicity enhance the depletion of pro-inflammatory macrophages and leukemia cells ex vivo. | Q40949603 |
| | Novel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entities | Q41033340 |
| | Expression and clinical significance of aminopeptidase N/CD13 in non-small cell lung cancer | Q41065836 |
| | Determination of the binding affinity of an anti-CD34 single-chain antibody using a novel, flow cytometry based assay | Q41126558 |
| | Biotechnological and gene therapeutic strategies in cancer treatment | Q41335396 |
| | Fc receptor biology | Q41464279 |
| | Investigation of the interaction between the class I MHC-related Fc receptor and its immunoglobulin G ligand. | Q42806469 |
| | Recombinant CD64-specific single chain immunotoxin exhibits specific cytotoxicity against acute myeloid leukemia cells. | Q44695773 |
| | Antigen targeting to dendritic cells with bispecific antibodies | Q46733858 |
| | The Fc-alpha receptor is a new target antigen for immunotherapy of myeloid leukemia. | Q51352382 |
| | Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16. | Q51773229 |
| | A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells. | Q51785972 |
| | In Vivo Applications of Single Chain Fv (Variable Domain) (scFv) Fragments | Q56568322 |
| | Clonal analysis of a human antimouse antibody (HAMA) response | Q78833903 |
| | Immunotoxins for targeted cancer therapy | Q79199423 |
| | Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16) | Q80393059 |
| | In vivo efficacy of the recombinant anti-CD64 immunotoxin H22(scFv)-ETA' in a human acute myeloid leukemia xenograft tumor model | Q82455492 |
| P433 | issue | 11 | |
| P304 | page(s) | 2159-2170 | |
| P577 | publication date | 2017-07-01 | |
| P1433 | published in | Journal of Cancer Research and Clinical Oncology | Q2081599 |
| P1476 | title | Efficient targeting of CD13 on cancer cells by the immunotoxin scFv13-ETA' and the bispecific scFv [13xds16]. | |
| P478 | volume | 143 | |